Neurocrine reports patient-reported outcome data from KINECT-PRO study
Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...
Hosted on MSN1mon
Neurocrine Biosciences’ Earnings Call: Record Sales & Strategic Growth
2024 marked a significant milestone for Neurocrine with INGREZZA achieving record sales, showing an impressive increase of approximately $475 million. This robust performance underscores the drug ...